EUVIMEDEUVIMED entdecken
Crossref

In vitro, intracellular and in vivo s ynergy between amoxicillin, imipenem and relebactam against Mycobacterium abscessus

Maria Bitar, Vincent Le Moigne, Jean-Louis Herrmann, Michel Arthur iD, Jean-Luc Mainardi

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Maria Bitar und 4 weiteren Autor:innen. Beteiligte Einrichtung: INSERM ERL 1336, UMRS 8228, Sorbonne Université-ENS-PSL-CNRS, Paris F-75006, France. Hauptthemen laut MEDLINE: Imipenem, Mycobacterium abscessus, Anti-Bacterial Agents, Azabicyclo Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Vaincre la Mucoviscidose, l'Association Grégory Lemarchal, l’Association Grégory Lemarchal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Mycobacterium abscessus is the most frequent of the rapidly growing mycobacteria responsible for lung infections in patients suffering from cystic fibrosis and COPD. Imipenem is currently recommended in the treatment of these infections in spite of β-lactamase production. Since the targets of β-lactams include transpeptidases of both the l,d and d,d specificities, we tested, in vitro, intracellularly and in vivo, a combination of two β-lactams active on these enzymes, amoxicillin and imipenem, alone or in combination with the β-lactamase inhibitor relebactam.

Methods

Drug combinations were evaluated against M. abscessus CIP 104536T and clinical isolates (n = 35) by determining MICs, FIC indices and time–killing. Drug combinations were also evaluated in macrophages and in mice.

Results

In the presence of relebactam, synergy between amoxicillin and imipenem was observed against both M. abscessus CIP 104536T and the clinical isolates. Against M. abscessus CIP 104536T, the addition of 1 mg/L imipenem and 4 mg/L relebactam led to a decrease in the MIC of amoxicillin from 64 to 1 mg/L. The triple combination was active in vitro and intracellularly (a 4.30 decrease in the log10 cfu/mL and 82% killing, respectively). The triple combination was effective in reducing log10 cfu in mouse organs and mouse spleen weights, and in preventing losses in mouse weights.

Conclusions

The amoxicillin/imipenem/relebactam combination was synergistic in vitro and effective in vivo against M. abscessus. Since these drugs are clinically available, the triple combination should be considered by clinicians and further evaluated based on the reporting of the patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImipenemMycobacterium abscessusAnti-Bacterial AgentsAzabicyclo CompoundsMycobacterium Infections, NontuberculousDrug SynergismAmoxicillinAnimalsMicrobial Sensitivity TestsMiceHumansMacrophagesbeta-Lactamase InhibitorsDrug Therapy, CombinationFemale

Substanzen

ImipenemAnti-Bacterial AgentsAzabicyclo CompoundsrelebactamAmoxicillinbeta-Lactamase Inhibitors

Autor:innen und Institutionen

  • INSERM ERL 1336, UMRS 8228, Sorbonne Université-ENS-PSL-CNRS, Paris F-75006, France.
  • Inserm, Université Paris-Saclay, UVSQ, Infection et inflammation, Montigny-Le-Bretonneux F-78180, France.
  • Assistance Publique-Hôpitaux de Paris, GHU Paris-Saclay, Service de Microbiologie, Hôpital Raymond Poincaré, Garches F-92380, France.
  • Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Université Paris Cité, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris F-75015, France.

ORCID-Profile: Michel Arthur

Förderung

  • Vaincre la Mucoviscidose
  • l'Association Grégory Lemarchal
  • l’Association Grégory Lemarchal

Zitieren

APA

Bitar, M., Le Moigne, V., Herrmann, J. L., Arthur, M., & Mainardi, J. L. (2025). In vitro, intracellular and in vivo s ynergy between amoxicillin, imipenem and relebactam against Mycobacterium abscessus. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf101

Vancouver

Bitar M, Le Moigne V, Herrmann JL, Arthur M, Mainardi JL. In vitro, intracellular and in vivo s ynergy between amoxicillin, imipenem and relebactam against Mycobacterium abscessus. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf101

BibTeX
@article{Bitar2025,
  author = {Bitar, Maria and Le Moigne, Vincent and Herrmann, Jean-Louis and Arthur, Michel and Mainardi, Jean-Luc},
  title = {In vitro, intracellular and in vivo s ynergy between amoxicillin, imipenem and relebactam against Mycobacterium abscessus},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf101}
}
Kostenlos starten →